Captech
7100 Forest Ave Ste 200, Richmond, Virginia, 23226, United States
Overview
CapTech was formed as the result of a friendship between the company's founders, Sandy Williamson and Slaughter Fitz-Hugh, that began while both were employed at Andersen Consulting in Washington, D.C. Eventually, each would leave the company to pursue other opportunities, but they stayed in touch. In March of 1997, the two found themselves back in their shared hometown–Richmond, Virginia–and this close proximity led to the creation of CapTech Ventures, Inc., an exceptional business partnership. The company has been successful from the very beginning, growing from $380,000 in revenue the first year to millions today. Always a privately held company, CapTech has thrived without the support of outside investors funding. Through partnership with clients and by providing exceptional service, CapTech has continued to grow and build on its successes. Now a full service information technology consultancy and the largest private IT-focused company headquartered in the region, CapTech performs services for a diverse and growing client base.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 5
Sector focus
- Consulting
- Information Technology
- Management Consulting
Investment portfolio
- Verley
Participated · Series A · Feb 2026
Verley engineers beta-lactoglobulin (BLG) whey proteins through precision fermentation, selling them under the FermWhey™ range to manufacturers looking for high-protein, clean-label and easily digestible ingredients. The proteins are functionalized to improve solubility, emulsification, gelling and nutritional profiles, enabling applications such as high-protein yoghurts and protein shots. By using fermentation rather than conventional dairy production, Verley claims to cut natural-resource consumption and help alleviate structural supply constraints in traditional whey. In less than four years, the company has secured self-affirmed GRAS status (2024) and an FDA “No Questions” letter (2025), validating product safety for the U.S. market. Verley holds a growing IP portfolio around both fermentation and protein functionalisation technologies that aim to outperform standard dairy proteins. The fresh capital will fund U.S. commercial rollout, early customer scale-up and increased production capacity, followed by planned expansion in Europe and the Middle East. Continued R&D investment is earmarked to push performance, efficiency and sustainability of its platform.